{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:32:11Z","timestamp":1791923531487,"version":"4.3.4"},"reference-count":113,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>\u03b2-thalassaemia is a rare genetic condition caused by mutations in the \u03b2-globin gene that result in severe iron-loading anaemia, maintained by a detrimental state of ineffective erythropoiesis (IE). The role of multiple mechanisms involved in the pathophysiology of the disease has been recently unravelled. The unbalanced production of \u03b1-globin is a major source of oxidative stress and membrane damage in red blood cells (RBC). In addition, IE is tightly linked to iron metabolism dysregulation, and the relevance of new players of this pathway, i.e., hepcidin, erythroferrone, matriptase-2, among others, has emerged. Advances have been made in understanding the balance between proliferation and maturation of erythroid precursors and the role of specific factors in this process, such as members of the TGF-\u03b2 superfamily, and their downstream effectors, or the transcription factor GATA1. The increasing understanding of IE allowed for the development of a broad set of potential therapeutic options beyond the current standard of care. Many candidates of disease-modifying drugs are currently under clinical investigation, targeting the regulation of iron metabolism, the production of foetal haemoglobin, the maturation process, or the energetic balance and membrane stability of RBC. Overall, they provide tools and evidence for multiple and synergistic approaches that are effectively moving clinical research in \u03b2-thalassaemia from bench to bedside.<\/jats:p>","DOI":"10.3390\/ijms22137229","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T22:02:04Z","timestamp":1625522524000},"page":"7229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Ineffective Erythropoiesis in \u03b2-Thalassaemia: Key Steps and Therapeutic Options by Drugs"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-0382","authenticated-orcid":false,"given":"Filomena","family":"Longo","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-814X","authenticated-orcid":false,"given":"Andrea","family":"Piolatto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-5788","authenticated-orcid":false,"given":"Giovanni Battista","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature25741","article-title":"Population snapshots predict early haematopoietic and erythroid hierarchies","volume":"555","author":"Tusi","year":"2018","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1073\/pnas.0909296106","article-title":"Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOH.0000000000000328","article-title":"Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis","volume":"24","author":"Dulmovits","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-01-548305","article-title":"Global transcriptome analyses of human and murine terminal erythroid differentiation","volume":"123","author":"An","year":"2014","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2008-03-077883","article-title":"Erythroblastic islands: Niches for erythropoiesis","volume":"112","author":"Chasis","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Koulnis, M., Liu, Y., Hallstrom, K., and Socolovsky, M. (2011). Negative autoregulation by Fas stabilizes adult erythropoiesis and accelerates its stress response. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021192"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Parisi, S., Finelli, C., Fazio, A., De Stefano, A., Mongiorgi, S., Ratti, S., Cappellini, A., Billi, A.M., Cocco, L., and Follo, M.Y. (2021). Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and \u03b2-Thalassemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020827"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOH.0000000000000132","article-title":"New insights into iron regulation and erythropoiesis","volume":"22","author":"Kim","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MOH.0b013e32834521c8","article-title":"Stress erythropoiesis: New signals and new stress progenitor cells","volume":"18","author":"Paulson","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.exphem.2020.07.011","article-title":"Stress erythropoiesis: Definitions and models for its study","volume":"89","author":"Paulson","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biocel.2014.03.029","article-title":"\u03b2-Thalassemia and Polycythemia vera: Targeting chronic stress erythropoiesis","volume":"51","author":"Crielaard","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V96.10.3624","article-title":"The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with \u03b2-thalassemia major","volume":"96","author":"Centis","year":"2000","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.blre.2017.10.001","article-title":"What can we learn from ineffective erythropoiesis in thalassemia?","volume":"32","author":"Oikonomidou","year":"2018","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2007-12-126938","article-title":"Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in \u03b2-thalassemia","volume":"112","author":"Libani","year":"2008","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.9734\/jpri\/2020\/v32i3130919","article-title":"The Role of Erythroferrone Hormone as Erythroid Regulator of Hepcidin and Iron Metabolism during Thalassemia and in Iron Deficiency Anemia\u2014A Short Review","volume":"32","author":"Talawy","year":"2020","journal-title":"J. Pharm. Res. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2141.1989.tb04285.x","article-title":"\u03b2 thalassaemia mutations in Mediterranean populations","volume":"71","author":"Cao","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2141.1992.tb08132.x","article-title":"Dominant \u03b2 thalassaemia: Molecular basis and pathophysiology","volume":"80","author":"Thein","year":"1992","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/35066048","article-title":"Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias","volume":"2","author":"Weatherall","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V79.11.3007.3007","article-title":"Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes","volume":"79","author":"Yuan","year":"1992","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.freeradbiomed.2016.12.024","article-title":"The mechanism of formation, structure and physiological relevance of covalent hemoglobin attachment to the erythrocyte membrane","volume":"103","author":"Welbourn","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fphys.2014.00084","article-title":"Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging","volume":"5","author":"Mohanty","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1179\/1607845413Y.0000000148","article-title":"Erythrocytic phosphatidylserine exposure and hemostatic alterations in \u03b2-thalassemia intermediate patients","volume":"19","author":"Zahedpanah","year":"2014","journal-title":"Hematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V70.1.158.158","article-title":"Erythrocyte membrane skeleton abnormalities in severe \u03b2-thalassemia","volume":"70","author":"Shinar","year":"1987","journal-title":"Blood"},{"key":"ref_24","first-page":"985210","article-title":"Oxidative stress and \u03b2-thalassemic erythroid cells behind the molecular defect","volume":"2013","author":"Bertoldi","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","article-title":"Iron overload in thalassemia: Different organs at different rates","volume":"2017","author":"Taher","year":"2017","journal-title":"Hematology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1566524018666181004121604","article-title":"Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in \u03b2-Thalassemia Patients","volume":"18","author":"Razak","year":"2018","journal-title":"Curr. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood.2020006425","article-title":"A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the \u03b3-globin gene in \u03b2-thalassemia","volume":"137","author":"Gong","year":"2021","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000205743","article-title":"Ferrokinetic measurement of erythropoiesis","volume":"79","author":"Beguin","year":"1988","journal-title":"Acta Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","article-title":"Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia","volume":"126","author":"Kautz","year":"2015","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to tango: Regulation of Mammalian iron metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1002\/jcp.30247","article-title":"Erythroferrone structure, function, and physiology: Iron homeostasis and beyond","volume":"236","author":"Srole","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of \u03b2-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.3324\/haematol.2018.213371","article-title":"Genetic loss of Tmprss6 alters terminal erythroid differentiation in a mouse model of \u03b2-thalassemia intermedia","volume":"104","author":"Stagg","year":"2019","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.17428","article-title":"SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of \u03b2-thalassaemia","volume":"194","author":"Vadolas","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0891-5849(02)00759-1","article-title":"Iron release, oxidative stress and erythrocyte ageing","volume":"32","author":"Comporti","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.01323","article-title":"Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs","volume":"11","author":"Bozza","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood-2019-122561","article-title":"Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial","volume":"134","author":"Porter","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12505","article-title":"The mutual control of iron and erythropoiesis","volume":"38","author":"Camaschella","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.12464","article-title":"Altered erythropoiesis and iron metabolism in carriers of thalassemia","volume":"94","author":"Cominal","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2016-09-742387","article-title":"Decreasing TfR1 expression reverses anemia and hepcidin suppression in \u03b2-thalassemic mice","volume":"129","author":"Li","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1182\/blood-2010-04-281360","article-title":"Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis","volume":"116","author":"Vieillevoye","year":"2010","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2018-05-852277","article-title":"Transferrin receptor 2 is a potential novel therapeutic target for \u03b2-thalassemia: Evidence from a murine model","volume":"132","author":"Artuso","year":"2018","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","article-title":"Iron metabolism under conditions of ineffective erythropoiesis in \u03b2-Thalassemia","volume":"133","author":"Rivella","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.vh.2015.06.003","article-title":"Mechanisms of BMP-Receptor Interaction and Activation","volume":"99","author":"Mueller","year":"2015","journal-title":"Vitam. Horm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-\u03b2 family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1111\/jcmm.15243","article-title":"Smad2\/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine \u03b2-thalassaemia by increasing GATA-1 availability","volume":"24","author":"Martinez","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of b-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.16156","article-title":"GDF11 contributes to hepatic hepcidin (HAMP) inhibition through SMURF1-mediated BMP-SMAD signalling suppression","volume":"188","author":"Fang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_51","first-page":"184","article-title":"Growth differentiation factor 15 in erythroid health and disease","volume":"17","author":"Tanno","year":"2010","journal-title":"Curr. Opin. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bcmd.2011.07.005","article-title":"Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with \u03b2 thalassemia intermedia","volume":"47","author":"Musallam","year":"2011","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V112.11.1881.1881","article-title":"Growth Differentiation Factor 15 (GDF15) and Erythropoietin (EPO) Levels in Beta Talassemia Major Patients","volume":"112","author":"Salussoglia","year":"2008","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"112346","DOI":"10.1016\/j.yexcr.2020.112346","article-title":"GDF-15 negatively regulates excess erythropoiesis and its overexpression is involved in erythroid hyperplasia","volume":"397","author":"Ranjbaran","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/MCB.25.4.1215-1227.2005","article-title":"GATA1 function, a paradigm for transcription factors in hematopoiesis","volume":"25","author":"Ferreira","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/iub.2192","article-title":"Regulation of GATA1 levels in erythropoiesis","volume":"72","author":"Caballero","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature13614","article-title":"HSP70 sequestration by free \u03b1-globin promotes ineffective erythropoiesis in \u03b2-thalassaemia","volume":"514","author":"Arlet","year":"2014","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/46809","article-title":"Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1","volume":"401","author":"Zeuner","year":"1999","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature05378","article-title":"Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1","volume":"445","author":"Ribeil","year":"2007","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2006-08-041830","article-title":"Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: Relevance to anemias","volume":"109","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2019001915","article-title":"Heme-regulated eIF2\u03b1 kinase in erythropoiesis and hemoglobinopathies","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene Therapy in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Frangoul, H., Altshuler, D., Cappellini, M.D., Chen, Y.-S., Domm, J., Eustace, B.K., Foell, J., de la Fuente, J., Grupp, S., and Handgretinger, R. (2020). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia. N. Engl. J. Med.","DOI":"10.1530\/ey.18.14.4"},{"key":"ref_64","first-page":"361","article-title":"Beyond transfusion therapy: New therapies in thalassemia including drugs, alternate donor transplant, and gene therapy","volume":"2018","author":"Porter","year":"2018","journal-title":"Hematol. 2014 Am. Soc. Hematol. Educ. Program Book"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","article-title":"Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with b-thalassemia","volume":"133","author":"Piga","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jcph.1696","article-title":"Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With \u03b2-Thalassemia","volume":"61","author":"Chen","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_68","unstructured":"Taher, A.T., Cappellini, M.D., Kattamis, A., Voskaridou, E., Perrotta, S., Piga, A., Filosa, A., Porter, J.B., Coates, T.D., and Forni, G.L. (2021, January 9\u201317). The beyond study: Results of a phase 2, double-blind, randomized, placebo-controlled multi center study of luspatercept in adult patients with non-transfusion dependent \u03b2-thalassemia. Proceedings of the 26th Congress of the European Hematology Association, Hague, The Netherlands. Available online: https:\/\/eha2021.ehaweb.org\/program\/eha\/eha2021\/en-US?filter=abstract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1902678","article-title":"Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency","volume":"381","author":"Grace","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_71","first-page":"abst-2600","article-title":"Proof of concept for the oral pyruvate kinase activator mitapivat in adults with non\u2013transfusion-dependent thalassemia: Interim results from an ongoing, phase 2, open-label, multicenter study","volume":"136","author":"Kuo","year":"2020","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.212589","article-title":"Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult \u03b2-thalassemia major","volume":"105","author":"Casu","year":"2020","journal-title":"Haematologica"},{"key":"ref_74","unstructured":"Nicholls, A., Likliter, J., Tozzi, L., Liu, D., and Shames, R. (2018, January 14\u201317). Hepcidin mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy. Proceedings of the 23rd Congress of the European Hematology Association, Stockholm, Sweden."},{"key":"ref_75","unstructured":"Lal, A., Piga, A., Viprakasit, V., Maynard, J., Kattamis, A., Yaeger, D., Byrnes, B., Chawla, L., and Tidmarsh, G. (2018, January 14\u201317). A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401 (Synthetic Human Hepcidin) in Patients with Iron Overload. Proceedings of the 23rd Congress of the European Hematology Association, Stockholm, Sweden."},{"key":"ref_76","unstructured":"Bourne, G., Li, Z., Brandari, A., Frederick, B., McMahon, J., and Tran, V. (2018, January 14\u201317). Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases. Proceedings of the 23rd Congress of the European Hematology Association, Stockholm, Sweden."},{"key":"ref_77","unstructured":"Lal, A., Voskaridou, E., Flevari, P., Taher, A., Chew, L.-P., Valone, F., Gupta, S., and Viprakasit, V. (2020, January 11\u201321). A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects. Proceedings of the 25th Congress of the European Hematology Association, Virtual Congress, Stockholm, Sweden."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.2073","article-title":"Transferrin therapy ameliorates disease in \u03b2-thalassemic mice","volume":"16","author":"Li","year":"2010","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.V40.2.239.239","article-title":"A family of congenital atransferrinemia","volume":"40","author":"Goya","year":"1972","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2014.117325","article-title":"Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3\/+ (Heterozygous b1\/b2 globin gene deletion) mice","volume":"100","author":"Gelderman","year":"2015","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe\u2212\/\u2212 mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2018-99-115339","article-title":"Transmembrane Protease, Serine 6 (TMPRSS6) Antisense Oligonucleotide (IONIS-TMPRSS6-LRX) Reduces Plasma Iron Levels of Healthy Volunteers in a Phase 1 Clinical Study","volume":"132","author":"McCaleb","year":"2018","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI129382","article-title":"Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of \u03b2-thalassemia","volume":"130","author":"Manolova","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.25670","article-title":"Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers","volume":"95","author":"Richard","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V69.4.1109.1109","article-title":"Fetal hemoglobin-containing cells have the same mean corpuscular hemoglobin as cells without fetal hemoglobin: A reciprocal relationship between gamma- and beta-globin gene expression in normal subjects and in those with high fetal hemoglobin production","volume":"69","author":"Dover","year":"1987","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood.2020005875","article-title":"Variable cells with identical genetic codes","volume":"135","author":"Babbs","year":"2020","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.molonc.2016.07.008","article-title":"A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity","volume":"10","author":"Crona","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","article-title":"A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease","volume":"8","author":"Pule","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1365-2141.2002.03958.x","article-title":"Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways","volume":"119","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2141.2012.09061.x","article-title":"Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia","volume":"157","author":"Flanagan","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jcph.1297","article-title":"Pharmacoproteomics Profiling of Plasma From \u03b2-Thalassemia Patients in Response to Hydroxyurea Treatment","volume":"59","author":"Zohaib","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01757-w","article-title":"A comprehensive review of hydroxyurea for \u03b2-haemoglobinopathies : The role revisited during COVID-19 pandemic","volume":"16","author":"Yasara","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1751-553X.2007.00965.x","article-title":"Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: Case reports and literature review","volume":"30","author":"Meo","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2020-041958","article-title":"Efficacy and safety of oral hydroxyurea in transfusion-dependent \u03b2-thalassaemia: A protocol for randomised double-blind controlled clinical trial","volume":"10","author":"Yasara","year":"2020","journal-title":"BMJ Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1078155220975825","article-title":"A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide","volume":"27","author":"Amare","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","article-title":"Pomalidomide reverses \u03b3-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors","volume":"127","author":"Dulmovits","year":"2016","journal-title":"Blood"},{"key":"ref_98","first-page":"63","article-title":"Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy","volume":"8","author":"Masera","year":"2010","journal-title":"Blood Transfus."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2008.03.001","article-title":"Thalidomide therapy in a patient with thalassemia major","volume":"41","author":"Perea","year":"2008","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12955","article-title":"Thalidomide induces haematologic responses in patients with \u03b2-thalassaemia","volume":"99","author":"Chen","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00277-018-3395-5","article-title":"Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia","volume":"97","author":"Ren","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-021-04501-3","article-title":"Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients","volume":"100","author":"Bhurani","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: Evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_104","unstructured":"Andemariam, B., Scheele, W., Gordeuk, V., Howard, J., Kanter, J., Eleftheriou, P., Pancham, S., Hagar, R., Clarke, L., and Gershwin, B. (2020, January 11\u201321). IMR-687, a highly selective phosphodiesterase 9 inhibitor (PDE9I), increases F-cells and fetal hemoglobin in a PH-2A interim analysis. Proceedings of the 25th Congress of the European Hematology Association, Hague, The Netherlands. Available online: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/295109\/."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0609.2006.00731.x","article-title":"Effects of rapamycin on accumulation of \u03b1-, \u03b2- and \u03b3-globin mRNAs in erythroid precursor cells from \u03b2-thalassaemia patients","volume":"77","author":"Fibach","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.bcmd.2020.102511","article-title":"Benserazide as a potential novel fetal hemoglobin inducer: An observational study in non-carriers of hemoglobin disorders","volume":"87","author":"Santos","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"102561","DOI":"10.1016\/j.bcmd.2021.102561","article-title":"Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease","volume":"89","author":"Pace","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1345.031","article-title":"Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-\u03b20-thalassemia: Considerations for treatment","volume":"1054","author":"Singer","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/08880019709009500","article-title":"Termination of transfusion dependence in beta-thalassemia: Two-year experience with recombinant human erythropoietin","volume":"14","author":"Kavakli","year":"1997","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood.2019004719","article-title":"Correcting \u03b2-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity","volume":"136","author":"Casu","year":"2020","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.26048","article-title":"Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model","volume":"96","author":"Schmidt","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI123191","article-title":"Bone marrow stromal cells from \u03b2-thalassemia patients have impaired hematopoietic supportive capacity","volume":"129","author":"Crippa","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.2019002721","article-title":"Hematopoietic stem cell function in \u03b2-thalassemia is impaired and is rescued by targeting the bone marrow niche","volume":"136","author":"Aprile","year":"2020","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:26:18Z","timestamp":1760163978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":113,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22137229"],"URL":"https:\/\/doi.org\/10.3390\/ijms22137229","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}